The report contains ten-year analysis with the following sections
contact us for pricing
Check out our sample pages |
Many companies now available
Search to find companies of interest
read summary of their published patent
the company report contains more information
nycomed | 848 |
takeda | 336 |
altana pharma | 82 |
4sc | 71 |
nps pharmaceuticals | 61 |
astrazeneca | 25 |
shire-nps pharmaceuticals | 19 |
nycomed asset management | 7 |
nycomed germany holding | 7 |
kist, michel | 7 |
Title of patent family (most common patent title) |
Family members |
Filing year |
---|---|---|
treatment of short bowel syndrome patients with colon-in-continuity | 64 | 2004 |
hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors | 61 | 2004 |
combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the … 🛈 | 55 | 2006 |
pyrazolone derivatives as pde4 inhibitors | 50 | 2007 |
ophthalmological use of roflumilast for the treatment of diseases of the eye | 50 | 2002 |
oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrro… 🛈 | 40 | 2002 |
3,4,4a,10b-tetrahydro-1h-thiopyrano-[4, 3-c] isoquinoline derivatives | 39 | 2009 |
dosage form containing pantoprazole as active ingredient | 38 | 2003 |
methylpyrrolopyrimidinecarboxamides | 34 | 2009 |
novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives | 34 | 2005 |